Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Department of Sexual Health and HIV, Birmingham University Hospitals NHS Foundation Trust, Birmingham, UK.
Transl Res. 2020 Jun;220:122-137. doi: 10.1016/j.trsl.2020.02.002. Epub 2020 Feb 29.
The sexually transmitted infection gonorrhea, caused by the Gram-negative bacterium Neisseria gonorrhoeae, can cause urethritis, cervicitis, and systemic disease, among other manifestations. N. gonorrhoeae has rapidly rising incidence along with increasing levels of antibiotic resistance to a broad range of drugs including first-line treatments. The rise in resistance has led to fears of untreatable gonorrhea causing substantial disease globally. In this review, we will describe multiple approaches being undertaken to slow and control this spread of resistance. First, a number of old drugs have been repurposed and new drugs are being developed with activity against Neisseria gonorrhoeae. Second, vaccine development, long an important goal, is advancing. Third, new diagnostics promise rapid detection of antibiotic resistance and a shift from empiric to tailored treatment. The deployment of these new tools for addressing the challenge of antibiotic resistance will require careful consideration to provide optimal care for all patients while extending the lifespan of treatment regimens.
淋病是一种由革兰氏阴性细菌淋病奈瑟菌引起的性传播感染,可以引起尿道炎、宫颈炎和全身性疾病等多种表现。淋病奈瑟菌对抗生素的耐药性不断上升,包括对一线治疗药物在内的多种药物的耐药性水平都在不断上升。这种耐药性的上升导致人们担心无法治愈的淋病会在全球范围内导致大量疾病。在这篇综述中,我们将描述正在采取多种方法来减缓和控制这种耐药性的传播。首先,许多旧药物被重新利用,并且正在开发具有抗淋病奈瑟菌活性的新药。其次,疫苗的开发,长期以来一直是一个重要目标,正在取得进展。第三,新的诊断方法有望快速检测抗生素耐药性,并从经验性治疗转向针对性治疗。为了应对抗生素耐药性的挑战,这些新工具的部署需要仔细考虑,以便在为所有患者提供最佳治疗的同时延长治疗方案的使用寿命。